VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia

Miramontes-González, José Pablo; Fernandez-Bueno, Iván; Isla, Leopoldo Pérez de; Alonso, Rodrigo; Muñiz-Grijalvo, Ovidio; Díaz‐Díaz, José Luis; Zambón, Daniel; Jiménez, Francisco Fuentes; Martín-Vallejo, Javier; Gude, Ana Elisa Rodríguez; Jiménez, David León; Padró, Teresa; González‐Sarmiento, Rogelio; Mata, Pedro

doi:10.1016/j.atherosclerosis.2019.03.019

Cited by 6 publications

(7 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…There are noteworthy useful impacts of OPG on vascular tissues as it is associated with endothelial dysfunction and IR. These effects were backed up previously by other studies; they documented an association between high serum OPG levels and cardiovascular disease [ 46 , 47 ]. Pennisi et al found that patients with plaques in both carotid and femoral districts showed a significant association between OPG serum levels and the number of plaques [ 48 ].…”

Section: Discussionmentioning

confidence: 60%

Osteoprotegerin expression and serum values in obese women with type 2 diabetes mellitus

et al. 2021

View full text Add to dashboard Cite

Background Obesity and diabetes prevalence are increasing worldwide. We aimed to detect the possible association of osteoprotegerin (OPG) gene expression with visceral adiposity indices and cardiometabolic risk factors among obese women. Methods and results The study enrolled 150 controls and 150 obese cases subdivided into two subgroups non-diabetic (n = 70) and 80 patients with type 2 diabetes mellitus (T2DM). Circulating OPG gene expression levels were figured out by real time PCR (Polymerase Chain Reaction). Serum OPG levels were assessed by Enzyme Linked Immunosorbent Assay. Our results explored that OPG serum levels were lower in the obese women compared to control group (p < 0.001) and obese diabetics had higher serum levels of OPG in comparison to obese non-diabetic patients (p < 0.001). Expression levels of OPG were higher in obese women than controls (p < 0.001). Moreover, the blood expression levels of OPG gene were higher in diabetic obese patients than non-diabetics. We found positive correlations between parameters of metabolic syndrome and obesity indices. After adjustment of the traditional risk factors, stepwise linear regression analysis test revealed that OPG expression levels were independently correlated with glycated hemoglobin, high-density lipoprotein-cholesterol, and waist-to-hip ratio. Conclusions OPG mRNA levels were associated with surrogate markers of insulin resistance in Egyptian obese women.

show abstract

Section: Discussionmentioning

confidence: 60%

Osteoprotegerin expression and serum values in obese women with type 2 diabetes mellitus

et al. 2021

View full text Add to dashboard Cite

show abstract

“…In the Spanish SAFEHEART registry, polymorphisms in the VEGFR and OPG genes, which encode vascular endothelial growth factor and osteoprotegerin, respectively, were associated with the accumulation of coronary calcium as measured with coronary tomographic angiography. 18 There have also been several separate reports from the Montreal associated with an increased incidence of coronary events. 28 That study also demonstrated that among patients classified as being at high genetic risk of CAD, a favourable lifestyle conferred a nearly 50% lower risk of CAD than an unfavourable lifestyle, highlighting the importance of lifestyle intervention in individuals with a high genetic burden for CAD.…”

Section: Discussionmentioning

confidence: 99%

“…There have been a few additional published investigations on the impact of common genetic variation on CAD risk in patients with FH. In the Spanish SAFEHEART registry, polymorphisms in the VEGFR and OPG genes, which encode vascular endothelial growth factor and osteoprotegerin, respectively, were associated with the accumulation of coronary calcium as measured with coronary tomographic angiography . There have also been several separate reports from the Montreal Clinic Research Institute that have demonstrated associations between SNPs within SLC22A3 , ABO , PCSK9 , LOX1 , PHACTR1 , LPA , and chromosome 9p21.3 locus with the presence of cardiovascular disease.…”

Section: Discussionmentioning

confidence: 99%

A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment

et al. 2019

View full text Add to dashboard Cite

Familial hypercholesterolaemia (FH) is associated with increased risk of coronary artery disease (CAD); however, risk prediction and stratification remain a challenge.Genetic risk scores (GRS) may have utility in identifying FH patients at high CAD risk.The study included 811 patients attending the lipid disorders clinic at Royal Perth Hospital with mutation-positive (n = 251) and mutation-negative (n = 560) FH. Patients were genotyped for a GRS previously associated with CAD. Associations between the GRS, clinical characteristics, and CAD were assessed using regression analyses. The average age of patients was 49.6 years, and 44.1% were male. The GRS was associated with increased odds of a CAD event in mutation-positive [odds ratio (OR) = 3.3; 95% confidence interval (CI) = 1.3-8.2; P = .009] and mutationnegative FH patients (OR = 1.8; 95% CI = 1.0-3.3; P = .039) after adjusting for established predictors of CAD risk. The GRS was associated with greater subclinical atherosclerosis as assessed by coronary artery calcium score (P = .039). A high GRS was associated with CAD defined clinically and angiographically in FH patients. High GRS patients may benefit from more intensive management including lifestyle modification and aggressive lipid-lowering therapy. Further assessment of the utility of the GRS requires investigation in prospective cohorts, including its role in influencing the management of FH patients in the clinic.

show abstract

“…These included SNPs from vitamin D receptor (VDR) [ 22 ], RANK ligand [ 23 ], transforming growth factor beta [ 24 ], toll-like receptor 4 [ 25 ], cytochrome c oxidase subunit II [ 26 ], S100 calcium binding protein A8 [ 27 ], N-acetyltransferase 2 [ 28 ], beta-carotene 15,15’-monooxygenase 1 [ 29 ], solute carrier family 23 member 1 [ 30 ], CD36 molecule [ 31 ], glycosyltransferase 6 domain containing 1 [ 32 ], and fibronectin [ 33 ]. Several of these candidate SNPs were chosen given contrasting previously reported associations with CVD, including ALR15 rs4311394 [ 34 ], CDKN2B-AS1 rs1333049 [ 35 ] and TNFRSF11B rs2073618 [ 36 ].…”

Section: Introductionmentioning

confidence: 99%

Association of TGFB1 rs1800469 and BCMO1 rs6564851 with coronary heart disease and IL1B rs16944 with all-cause mortality in men from the Northern Ireland PRIME study

Mooney

Linden²,

Winning³

et al. 2022

PLoS ONE

View full text Add to dashboard Cite

Background Historically, high levels of morbidity and mortality have been associated with cardiovascular disease in the Northern Ireland population. Previously reported associations between single nucleotide polymorphisms (SNPs) and cardiovascular disease within other populations have not always been consistent. Objective To investigate associations between 33 SNPs with fatal or non-fatal incident coronary heart disease (CHD) events and all-cause mortality in the Northern Irish participants of the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Method Phase 2 of the PRIME study prospectively evaluated 2,010 men aged 58–74 years in Northern Ireland for more than 10 years for incident CHD events (myocardial infarction, percutaneous coronary intervention, coronary artery bypass, and cardiac death) and more than 15 years for all-cause mortality. SNPs previously reported in association with cardiovascular outcomes were evaluated against incident CHD events and all-cause mortality using Cox’s proportional hazards models adjusted for established cardiovascular disease risk factors. Results During the follow-up period, 177 incident CHD events were recorded, and 821 men died. Both BCMO1 rs6564851 (Hazard ratio [HR] = 0.76; 95% confidence intervals [CI]: 0.60–0.96; P = 0.02) and TGFB1 rs1800469 (HR = 1.30; CI: 1.02–1.65; P = 0.04) were significantly associated with incident CHD events in adjusted models. Only IL1B rs16944 was significantly associated with all-cause mortality (HR = 1.18; CI: 1.05–1.33; P = 0.005). No associations remained significant following Bonferonni correction for multiple testing. Conclusion We report a novel association between BCMO1 rs6564851 and risk of incident CHD events. In addition, TGFB1 rs1800469 and IL1B rs16944 were associated with the risk of incident CHD events and all-cause mortality outcomes respectively, supporting previously reported associations.

show abstract

VEGFR2 and OPG genes modify the risk of subclinical coronary atherosclerosis in patients with familial hypercholesterolemia

Cited by 6 publications

References 30 publications

Osteoprotegerin expression and serum values in obese women with type 2 diabetes mellitus

Osteoprotegerin expression and serum values in obese women with type 2 diabetes mellitus

A genetic risk score predicts coronary artery disease in familial hypercholesterolaemia: enhancing the precision of risk assessment

Association of TGFB1 rs1800469 and BCMO1 rs6564851 with coronary heart disease and IL1B rs16944 with all-cause mortality in men from the Northern Ireland PRIME study

Contact Info

Product

Resources

About